Generex Biotechnology to Present Clinical Data at the 9th Annual Canadian Diabetes Association / Canadian Society of Endocrinology and Metabolism Prof
21 October 2005Generex Biotechnology Corporation (NASDAQ: GNBT), a
leader in the area of buccal drug delivery, today announced that the
Company will make three poster presentations of Oral-lyn™ clinical data on
behalf of the Company at the 9th Annual Canadian Diabetes Association /
Canadian Society of Endocrinology and Metabolism Professional Conference
and Annual Meetings to be held in Edmonton, Alberta, from October 20 - 22,
2005. The three presentations are as follows:
-- "A Series of Open-label Studies Comparing Various Formulation of
Orally Administered Insulin (Oral-lyn™) in Patients with Type-1 Diabetes
Mellitus (DM)," a study coauthored by Dr. Jaime Guevara-Aguirre, Marco
Guevara, and Jeannette Saavedra, all of the Institute of Endocrinology
IEMYR in Quito, Ecuador;
-- "A 12-Day Comparison of Preprandial Humulin® vs. Oral-lyn™ in
10 Type 1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy," a
study coauthored by Dr. Jaime Guevara-Aguirre, Marco Guevara, and Jeannette
Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador;
-- "Addition of Oral-lyn™ at Mealtimes in Subjects with Type 2
Diabetes Maintained on Glargine + Metformin - A Comparison with Placebo," a
study coauthored by Professor Itamar Raz of Hadassah Hospital, Jerusalem,
Israel together with M. Kidron (also of Hadassah Hospital) and M. Dubinsky
and J. Wainstein of Wolfson Hospital, Holon, Israel.
The professional conference and annual meetings bring together educators,
clinicians, and scientists to share their expertise, ideas, and experiences
in diabetes and other endocrine disorders.
About Generex
Generex is engaged in the research and development of drug delivery systems
and technologies. Generex has developed a proprietary platform technology
for the delivery of drugs into the human body through the oral cavity (with
no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the
body by the lining of the inner mouth using the Company's proprietary
RapidMist™ device. The Company's flagship product, oral insulin
(Oral-lyn™), which has been approved for commercial sale in Ecuador for
the treatment of patients with Type-1 and Type-2 diabetes, is in various
stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to
time by Generex representatives concerning the same subject matter may
contain "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements can be
identified by introductory words such as "expects," "plans," "intends,"
"believes," "will," "estimates," "forecasts," "projects" or words of
similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Forward-looking statements frequently are
used in discussing potential product applications, potential
collaborations, product development activities, clinical studies,
regulatory submissions and approvals, and similar operating matters. Many
factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Known
risks and uncertainties include those identified from time to time in the
reports filed by Generex with the Securities and Exchange Commission,
which should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or events, and
one should avoid placing undue reliance on such statements. Generex claims
the protection of the safe harbor for forward-looking statements that is
contained in the Private Securities Litigation Reform Act.
Shayne Gilliatt of Generex Biotechnology Corporation
+1-800-391-6755
+1-416-364-2551
Or
Ed Lewis of CEOcast, Inc.
for Generex Biotechnology Corporation
+1-212-732-4300
Email Contact
SOURCE: Generex
Source: Marketwire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Articles
|
